Astrazeneca annual net debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Net Debt Growth & History (AZN)
Astrazeneca's net debt was $25.71B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.71B | −$545.0M | −2.08% |
| 2024 | 2024-12-31 | $26.26B | $2.35B | +9.82% |
| 2023 | 2023-12-31 | $23.91B | −$109.0M | −0.45% |
| 2022 | 2022-12-31 | $24.02B | −$1.42B | −5.58% |
| 2021 | 2021-12-31 | $25.44B | $12.21B | +92.30% |
| 2020 | 2020-12-31 | $13.23B | −$304.0M | −2.25% |
| 2019 | 2019-12-31 | $13.53B | −$749.0M | −5.24% |
| 2018 | 2018-12-31 | $14.28B | −$201.0M | −1.39% |
| 2017 | 2017-12-31 | $14.48B | $2.69B | +22.84% |
| 2016 | 2016-12-31 | $11.79B | $2.98B | +33.78% |
| 2015 | 2015-12-31 | $8.81B | — | — |
Astrazeneca quarterly net debt
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27.35B | −$68.0M | −0.25% |
| Q1 2026 | 2026-03-31 | $26.36B | — | — |
| Q4 2025 | 2025-12-31 | $25.71B | −$545.0M | −2.08% |
| Q3 2025 | 2025-09-30 | $24.49B | — | — |
| Q2 2025 | 2025-06-30 | $27.41B | −$444.0M | −1.59% |
| Q4 2024 | 2024-12-31 | $26.26B | $2.35B | +9.82% |
| Q2 2024 | 2024-06-30 | $27.86B | $2.73B | +10.87% |
| Q4 2023 | 2023-12-31 | $23.91B | −$109.0M | −0.45% |
| Q2 2023 | 2023-06-30 | $25.13B | −$489.0M | −1.91% |
| Q4 2022 | 2022-12-31 | $24.02B | −$1.42B | −5.58% |
| Q2 2022 | 2022-06-30 | $25.62B | $13.00B | +103.01% |
| Q4 2021 | 2021-12-31 | $25.44B | $12.21B | +92.30% |
| Q2 2021 | 2021-06-30 | $12.62B | −$2.10B | −14.24% |
| Q4 2020 | 2020-12-31 | $13.23B | −$304.0M | −2.25% |
| Q2 2020 | 2020-06-30 | $14.71B | −$283.0M | −1.89% |
| Q4 2019 | 2019-12-31 | $13.53B | −$749.0M | −5.24% |
| Q2 2019 | 2019-06-30 | $15.00B | −$1.69B | −10.14% |
| Q4 2018 | 2018-12-31 | $14.28B | −$201.0M | −1.39% |
| Q2 2018 | 2018-06-30 | $16.69B | — | — |
| Q4 2017 | 2017-12-31 | $14.48B | — | — |
Astrazeneca net debt trends
Over the last five fiscal years, Astrazeneca's net debt increased from $13.23B to $25.71B, a change of $12.48B. The latest reported quarter, Q2 2026, shows $27.35B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...